Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage.
Cancer Discov
; 14(8): 1366-1368, 2024 Aug 02.
Article
en En
| MEDLINE
| ID: mdl-39091204
ABSTRACT
Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non-small cell lung cancer treated with lifileucel, a cell therapy product based on autologous tumor-infiltrating lymphocytes (TIL). Extending solid evidence in advanced melanoma that led to FDA approval of lifileucel, this new evidence bodes well for treating patients with other common tumor histologies, justifying important efforts by a large number of academic and biotechnology companies engaged in improving the TIL process. See related article by Schoenfeld et al., p. 1389 (1).
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Inmunoterapia Adoptiva
/
Linfocitos Infiltrantes de Tumor
/
Carcinoma de Pulmón de Células no Pequeñas
/
Neoplasias Pulmonares
Límite:
Humans
Idioma:
En
Revista:
Cancer Discov
Año:
2024
Tipo del documento:
Article